Free tool
FAERS Monitor: Simponi Aria
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125433 or its brand name (Simponi Aria, Golimumab). Reports on generic versions are filed under their own applications.
Reports
12,593
Serious
9,544
76% of reports
Hospitalization
4,405
Death reported
2,708
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,916
- off label use2,949
- pain2,949
- rheumatoid arthritis2,927
- fatigue2,768
- alopecia2,587
- rash2,513
- systemic lupus erythematosus2,509
- abdominal discomfort2,482
- pemphigus2,476
- glossodynia2,470
- hypersensitivity2,434
- hand deformity2,409
- infusion related reaction2,350
- wound2,328
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 124 |
| 2010 | 170 |
| 2011 | 304 |
| 2012 | 243 |
| 2013 | 200 |
| 2014 | 124 |
| 2015 | 594 |
| 2016 | 405 |
| 2017 | 590 |
| 2018 | 752 |
| 2019 | 768 |
| 2020 | 775 |
| 2021 | 1,050 |
| 2022 | 1,243 |
| 2023 | 1,034 |
| 2024 | 1,785 |
| 2025 | 1,676 |
| 2026 | 756 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,566 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 2,476 | 412.1 | 395.8 | 814,753 |
| hand deformitySignal | 2,409 | 375.4 | 360.5 | 734,736 |
| glossodyniaSignal | 2,470 | 207.0 | 199.3 | 450,836 |
| woundSignal | 2,328 | 151.6 | 145.9 | 319,687 |
| systemic lupus erythematosusSignal | 2,509 | 127.0 | 122.4 | 291,781 |
| infusion related reactionSignal | 2,350 | 61.4 | 59.1 | 134,937 |
| rheumatoid arthritisSignal | 2,927 | 44.2 | 42.8 | 120,935 |
| abdominal discomfortSignal | 2,482 | 25.1 | 24.2 | 56,936 |
| alopeciaSignal | 2,587 | 22.3 | 21.5 | 52,362 |
| hypersensitivitySignal | 2,434 | 22.2 | 21.4 | 48,989 |
| rashSignal | 2,513 | 9.7 | 9.3 | 19,847 |
| painSignal | 2,949 | 8.1 | 7.8 | 18,665 |
| fatigueSignal | 2,768 | 6.0 | 5.8 | 11,806 |
| off label useSignal | 2,949 | 5.6 | 5.5 | 11,704 |
| drug ineffectiveSignal | 3,916 | 5.0 | 4.8 | 13,223 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.